1 July 2020 in Journal of Endourology
Introduction Rezūm water vapor thermal ablation is a new minimally invasive technique used to treat benign prostatic hyperplasia (BPH). Major advantages include minimal anesthesia and recovery time, low rate of sexual side effects and durable clinical improvement. However data is lacking regarding use of Rezūm in prostate glands >80cc. Here we seek to examine clinical outcomes of men with large prostate glands following Rezūm. Methods We retrospectively reviewed patients who underwent Rezūm therapy at our institution since 7/2017. Three month postoperative outcomes were analyzed including AUA symptom score, peak flow, and post-void residual. Complications, including hematuria and urinary tract infections, were also assessed. All statistical analyses were conducted using RStudio 1.2.1335. Results 182 patients undergoing Rezūm were identified of which 25.8% had prostate volume >80cc. Mean gland volume in this group was 119cc and 55.3% were catheter dependent. Following Rezūm, statistically significant improvement was seen in AUASS from 22 to 13.4 (p=0.04) and post-void residual from 305cc to 149cc (0.05). Statistically significant improvement was seen in peak flow rate from 7.7 mL/second to 12.7 mL/second (p=0.002). In a subset of catheter dependent patients, the postoperative catheter free rate was 83% for men with glands >80cc which was comparable to 88% in the smaller gland group. Postoperative complication rate was not significantly different between large or small glands. Conclusions In our experience, Rezūm is efficacious in patients with glands >80cc. Patients experience symptomatic and objective improvement in voiding parameters that is comparable to patients with glands smaller than 80cc. Among catheter dependent patients with glands >80cc, over 80% are catheter free after Rezūm. Our experience supports the consideration of Rezūm in patients with prostate glands >80cc; further studies are warranted to confirm long-term outcomes.
7 January 2021 in The Journal of Sexual Medicine
Peyronie's disease (PD) is a challenging clinical entity. To assist clinicians with diagnosis and management, four separate organizations have published PD guidelines over the past five years, but there remains a lack of consensus and data-driven recommendations for many aspects of diagnosis and treatment. To compare and contrast PD guidelines, highlighting key similarities and differences among the guideline panel recommendations and identify areas for further research. We performed an extensive review to compare and contrast diagnosis and treatment recommendations from publically available published PD guidelines from four different organizations: American Urological Association, European Association of Urology, Canadian Urologic Association, and the International Society of Sexual Medicine. Key similarities and differences with regards to definition, evaluation, nonsurgical and surgical treatments were compared. Points of general consensus among the guideline panels included: History is adequate for diagnosis of PD, and intracavernosal injection is a gold standard to evaluate penile deformity prior to invasive intervention. Careful counseling with shared decision-making is required prior to treatment. In general, plication and incision and/or grafting surgery is reserved for patients with preserved erectile function whereas penile prosthesis implantation is the only surgical option for PD patients with erectile dysfunction. Overall, nonsurgical treatments have inferior evidence of efficacy with these being the main area of controversy; however, all societies recognize that intralesional injections may be used. 0Further research into the pathophysiology of PD may direct novel treatments targeted towards early intervention and rigorous outcomes research may direct best practices for the surgical treatment of PD in the future. PD is a challenging clinical entity. Direct comparison of the published PD guidelines highlights clear standards of care as well as areas where more research is needed to promote higher levels of evidence-based practice. To our knowledge this is the first report to directly compare and contrast published guidelines pertaining to the diagnosis and management of PD. Limitations include the lack of evidence-quality review pertaining to individual guideline recommendations, although this was not the aim of this review. We highlight consensus of major urologic societies on many aspects of work up and management of PD with notable exceptions which may guide further research. Manka MG, White LA, Yafi FA, et al. Comparing and Contrasting Peyronie's Disease Guidelines: Points of Consensus and Deviation. J Sex Med 2021;18:363-375.
1 January 2022 in Sexual Medicine Reviews
Persistent genital arousal disorder (PGAD) is an uncommon condition resulting in intrusive, unwanted and distressing symptoms of genital arousal. Presentation can vary and most cases do not have an immediately identifiable etiology. To present evaluation and treatment recommendations for PGAD from a multidisciplinary perspective and provide case examples. A focused review of the literature on diagnosis, workup, and treatment of PGAD was completed. A case series of 3 varying presentations of PGAD is offered. PGAD results in high levels of patient distress and is best managed with a multidisciplinary treatment approach. Identification and management of co-occurring symptoms or disease states is imperative, particularly psychologic and psychiatric comorbidities. With appropriate intervention, patients may achieve improvement of their physical symptoms and a decrease in associated psychological distress. PGAD is an uncommon and highly distressing condition that requires thoughtful evaluation for appropriate diagnosis and treatment. Multidisciplinary treatment approaches provide the best opportunity to address the needs of patients and optimizing treatment response. Pease ER, Ziegelmann M, Vencill JA, et al. Persistent Genital Arousal Disorder (PGAD): A Clinical Review and Case Series in Support of Multidisciplinary Management. Sex Med Rev 2022;10:53-70.